PET-Technology is a federal network of medical centers for the diagnosis and treatment of cancer and the production of radiopharmaceuticals.
Business Model:
Revenue: $0
Employees: 11-50
PET-Technology was acquired by
Pharmstandard.
The acquisition happend on 2018-07-18.
Details of the transaction were not public
Address:
City: Moscow
State: Moscow City
Zip:
Country: Russian Federation
PET provide the PET centers with the radiopharmaceuticals, the project company will establish production of isotope 18O and organize two cyclotron sites—in Lipetsk and Ufa—for production of short-lived isotopes. PET is used for the diagnosis of cancers, including diagnosis in early stages, and for diagnosis and treatment in cardiology and neurology. Radiopharmaceuticals are selectively absorbed by tumor tissues and tissues whose metabolic activity is high. By combining into one instrument the functions of PET and computer tomography, benefits of both ensue—a three-dimensional picture of functional changes in tissue overlays a high-resolution image of the patient’s organs. PET diagnostics identify 18 percent more tumors in early stages, significantly improving prognoses and decreasing mortality.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|